SG11201702741SA - Heteroaryl compounds as irak inhibitors and uses thereof - Google Patents
Heteroaryl compounds as irak inhibitors and uses thereofInfo
- Publication number
- SG11201702741SA SG11201702741SA SG11201702741SA SG11201702741SA SG11201702741SA SG 11201702741S A SG11201702741S A SG 11201702741SA SG 11201702741S A SG11201702741S A SG 11201702741SA SG 11201702741S A SG11201702741S A SG 11201702741SA SG 11201702741S A SG11201702741S A SG 11201702741SA
- Authority
- SG
- Singapore
- Prior art keywords
- heteroaryl compounds
- irak inhibitors
- irak
- inhibitors
- heteroaryl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462082231P | 2014-11-20 | 2014-11-20 | |
PCT/US2015/061463 WO2016081679A1 (en) | 2014-11-20 | 2015-11-19 | Heteroaryl compounds as irak inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201702741SA true SG11201702741SA (en) | 2017-04-27 |
Family
ID=54705914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201702741SA SG11201702741SA (en) | 2014-11-20 | 2015-11-19 | Heteroaryl compounds as irak inhibitors and uses thereof |
Country Status (24)
Country | Link |
---|---|
US (2) | US9790221B2 (en) |
EP (1) | EP3221306B1 (en) |
JP (1) | JP6787892B2 (en) |
KR (2) | KR20230158647A (en) |
CN (1) | CN107108561B (en) |
AR (1) | AR103138A1 (en) |
AU (1) | AU2015349899B9 (en) |
CA (1) | CA2964982C (en) |
DK (1) | DK3221306T3 (en) |
ES (1) | ES2772133T3 (en) |
HR (1) | HRP20200179T1 (en) |
HU (1) | HUE047586T2 (en) |
IL (1) | IL252346B (en) |
LT (1) | LT3221306T (en) |
MX (1) | MX2017006266A (en) |
NZ (1) | NZ730728A (en) |
PL (1) | PL3221306T3 (en) |
PT (1) | PT3221306T (en) |
RS (1) | RS59974B1 (en) |
RU (1) | RU2743718C2 (en) |
SG (1) | SG11201702741SA (en) |
SI (1) | SI3221306T1 (en) |
WO (1) | WO2016081679A1 (en) |
ZA (1) | ZA201702402B (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3286181B1 (en) | 2015-04-22 | 2021-01-27 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds and method for making and using the compounds |
MA43677A (en) * | 2016-02-25 | 2018-11-28 | Asceneuron Sa | GLYCOSIDASE INHIBITORS |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
WO2018089199A1 (en) | 2016-10-26 | 2018-05-17 | Rigel Pharmaceuticals, Inc. | Oxazole derivatives for use as irak inhibitors and method for their preparation |
US10414753B2 (en) | 2016-10-26 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Amide compounds and method for making and using |
US10975055B2 (en) | 2016-11-22 | 2021-04-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
SG11201906681PA (en) * | 2017-02-01 | 2019-08-27 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
JOP20180011A1 (en) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES |
US11053225B2 (en) * | 2017-05-02 | 2021-07-06 | Korea Research Institute Of Chemical Technology | Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating Tyro 3 related disease comprising same as active ingredient |
JP2020525513A (en) * | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamidobicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1 as an ATF4 inhibitor for treating cancer and other diseases -Carboxamide derivatives and related compounds |
SG11202000532SA (en) * | 2017-08-09 | 2020-02-27 | Denali Therapeutics Inc | Compounds, compositions and methods |
EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
IL307995A (en) | 2017-09-22 | 2023-12-01 | Kymera Therapeutics Inc | Protein degraders and uses thereof |
IL304055A (en) | 2017-12-26 | 2023-08-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
TWI721483B (en) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
TWI727392B (en) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | Thiadiazole irak4 inhibitors |
JP2022516401A (en) | 2018-11-30 | 2022-02-28 | カイメラ セラピューティクス, インコーポレイテッド | IRAK Degradants and Their Use |
MX2021009669A (en) | 2019-02-13 | 2021-10-13 | Denali Therapeutics Inc | Compounds, compositions and methods. |
AR119857A1 (en) | 2019-08-30 | 2022-01-19 | Rigel Pharmaceuticals Inc | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF AND THEIR USE FOR THE INHIBITION OF AN IRAQ PROTEIN |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
MX2022007576A (en) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Irak degraders and uses thereof. |
TW202210483A (en) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Crystalline forms of irak degraders |
EP4320103A1 (en) * | 2021-04-09 | 2024-02-14 | Quanta Therapeutics, Inc. | Pyrimidine based ras modulators and uses thereof |
CN116514769B (en) * | 2022-01-21 | 2024-02-27 | 中国药科大学 | 4-hydroxy pyrimidine-5-formylhydrazone derivative, preparation method, pharmaceutical composition and application |
WO2023154766A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009026377A1 (en) * | 2007-08-20 | 2009-02-26 | Board Of Regents, The University Of Texas System | Metal-containing polymers and uses thereof |
WO2009054253A1 (en) * | 2007-10-26 | 2009-04-30 | Konica Minolta Holdings, Inc. | Organic electroluminescent device, display device and illuminating device |
MX2011001127A (en) | 2008-08-04 | 2011-03-21 | Merck Patent Gmbh | Novel phenylamino isonicotinamide compounds. |
CA2757671A1 (en) * | 2009-04-03 | 2010-10-07 | Cellzome Ag | Methods for the identification of kinase interacting molecules and for the purification of kinase proteins |
JP2011098948A (en) * | 2009-06-25 | 2011-05-19 | Yamagata Promotional Organization For Industrial Technology | Bipyridine derivative and organic electroluminescent element containing the same |
CA2782885A1 (en) * | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
CA2802641C (en) * | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
EP2822956A1 (en) * | 2012-03-07 | 2015-01-14 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
US20150041789A1 (en) * | 2012-03-22 | 2015-02-12 | Konica Minolta, Inc. | Transparent electrode, electronic device, and organic electroluminescent element |
KR20150033716A (en) * | 2012-07-10 | 2015-04-01 | 아레스 트레이딩 에스.에이. | Pyrimidine pyrazolyl derivatives |
ES2728403T3 (en) * | 2014-01-09 | 2019-10-24 | Merck Patent Gmbh | Pyrimidin pyrazolyl derivatives and their use as IRAK inhibitors |
-
2015
- 2015-11-19 NZ NZ730728A patent/NZ730728A/en unknown
- 2015-11-19 KR KR1020237038922A patent/KR20230158647A/en active IP Right Grant
- 2015-11-19 ES ES15801650T patent/ES2772133T3/en active Active
- 2015-11-19 SI SI201531094T patent/SI3221306T1/en unknown
- 2015-11-19 CA CA2964982A patent/CA2964982C/en active Active
- 2015-11-19 MX MX2017006266A patent/MX2017006266A/en active IP Right Grant
- 2015-11-19 CN CN201580073060.9A patent/CN107108561B/en active Active
- 2015-11-19 EP EP15801650.1A patent/EP3221306B1/en active Active
- 2015-11-19 AU AU2015349899A patent/AU2015349899B9/en active Active
- 2015-11-19 JP JP2017527260A patent/JP6787892B2/en active Active
- 2015-11-19 RS RS20200153A patent/RS59974B1/en unknown
- 2015-11-19 WO PCT/US2015/061463 patent/WO2016081679A1/en active Application Filing
- 2015-11-19 KR KR1020177015188A patent/KR20170086057A/en not_active Application Discontinuation
- 2015-11-19 RU RU2017120274A patent/RU2743718C2/en active
- 2015-11-19 HU HUE15801650A patent/HUE047586T2/en unknown
- 2015-11-19 US US14/945,610 patent/US9790221B2/en active Active
- 2015-11-19 LT LTEP15801650.1T patent/LT3221306T/en unknown
- 2015-11-19 SG SG11201702741SA patent/SG11201702741SA/en unknown
- 2015-11-19 PT PT158016501T patent/PT3221306T/en unknown
- 2015-11-19 PL PL15801650T patent/PL3221306T3/en unknown
- 2015-11-19 DK DK15801650.1T patent/DK3221306T3/en active
- 2015-11-20 AR ARP150103793A patent/AR103138A1/en unknown
-
2017
- 2017-04-05 ZA ZA2017/02402A patent/ZA201702402B/en unknown
- 2017-05-17 IL IL252346A patent/IL252346B/en active IP Right Grant
- 2017-09-12 US US15/701,842 patent/US10030013B2/en active Active
-
2020
- 2020-02-04 HR HRP20200179TT patent/HRP20200179T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201702402B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
ZA201801056B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
HRP20190506T1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
ZA201800975B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
ZA201701501B (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
IL247057B (en) | Heteroaryl syk inhibitors | |
IL246785A0 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
EP3134091A4 (en) | Irak inhibitors and uses thereof | |
HK1226398A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
SG11201706029VA (en) | Anti-senescence compounds and uses thereof | |
HK1246780A1 (en) | Aza-pyridone compounds and uses thereof | |
ZA201705456B (en) | Benzoxaborole compounds and uses thereof | |
IL253459B (en) | Isoergoline compounds and uses thereof | |
GB201718875D0 (en) | Autophagy-inhibiting compounds and uses thereof | |
GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |